Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co EBITDA per Employee

The EBITDA per Employee of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Nov 20, 2026 is 280,239.58 CNY. In the previous year, EBITDA per Employee was 438,151.00 CNY — a change of -36.04% (lower).

EBITDA per Employee

280,239.58CNY

YoY

-36.04%

Last updated:

EBITDA per Employee of Pacific Shuanglin Bio-pharmacy Co is 2025 280,239.58 CNY. EBITDA per Employee of Pacific Shuanglin Bio-pharmacy Co was 2024 438,151.00 CNY. It decreases by -36.04% lower compared to the previous year.

The Pacific Shuanglin Bio-pharmacy Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
57,746.09 CNY
Jan 1, 2019
96,960.39 CNY
Jan 1, 2020
115,669.35 CNY
Jan 1, 2021
237,403.07 CNY
Jan 1, 2022
335,801.77 CNY
Jan 1, 2023
352,934.07 CNY
Jan 1, 2024
438,151.00 CNY
Jan 1, 2025
280,239.58 CNY
The Pacific Shuanglin Bio-pharmacy Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
280,239.58CNY-36.04%
438,151.00CNY+24.15%
352,934.07CNY+5.10%
335,801.77CNY+41.45%
237,403.07CNY+105.24%
115,669.35CNY+19.30%
96,960.39CNY+67.91%
57,746.09CNY+9.94%
52,525.67CNY+27.57%
41,174.75CNY-8.44%
44,967.98CNY-22.51%
58,027.31CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

EBITDA per Employee of Pacific Shuanglin Bio-pharmacy Co is 280,239.58 CNY in 2025.

EBITDA per Employee of Pacific Shuanglin Bio-pharmacy Co changed from 438,151.00 CNY to 280,239.58 CNY, representing a -36.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Pacific Shuanglin Bio-pharmacy Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Pacific Shuanglin Bio-pharmacy Co

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co